SARomics Biostructures company logo

Accelerating Discovery Through Structural Insight

Company and Business Model

SARomics Biostructures is a research-intensive contract research organization (CRO), which provide services in protein crystallization, protein crystallography, antibody-antigen and biosimilars structure characterization, protein NMR spectroscopy and structure-based drug design. Our labs and Headquarters are located in Lund, Sweden, at Medicon Village, a research center created at the former Astra Zeneca site in Lund. The company was founded in 2006 and quickly established itself as a premium provider of structural biology services. We work with small- and medium-size biotech companies, large pharma and academic groups from North and South America, Asia, Europe, Scandinavia and Australia. SARomics Biostructures is managed by a highly experienced team of professionals with many years of solid industrial and academic research background and with complementary key expertise in all areas of structural biology and structure-based drug design.

SARomics Biostructures services are provided on a fee-for-service basis with a project-based payment schedule, which includes a startup fee and additional milestone-based payments. FTE-based payment may also be applied upon agreement with the customer.


Please view a detailed company presentation on the right and a short overview of our business partners below.

View our latest company presentation (slide show) with details of our services!

Business Partners

Red Glead Discovery offers first-rate research services for drug discovery. In-house laboratory capabilities comprise medicinal chemistry, biology, analytical chemistry and ADME. An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.


CARNA BIOSCIENCES, Inc is a biopharmaceutical company focused on the discovery and development of proprietary kinase inhibitor drugs to treat serious unmet medical needs. By leveraging expertise and experiences accumulated through its own drug discovery efforts, Carna has established extensive distribution channels as a reliable service provider, and has proven to be an excellent supplier of high-quality drug discovery support services to scientists worldwide. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna is a publicly traded company in the JASDAQ of the Tokyo Stock Exchange with securities code, 4572.
Among the drug discovery supporting products and services Carna Biosciences provides:
1. Kinase Protein
2. Profiling Services
3. Assay Development
5. Cell Based Assay Services
Carna Biosciences markets SARomics Biostructures crystallography services in Japan.


inSili.com offers an elite source of intellectual property and unique expertise for innovative pharmaceutical and biotechnological research and development. The company provides know-how and world-leading technology for virtual screening of pioneering de novo designed molecular agents.
inSili.com's founders created and defined the terms "scaffold-hopping" and "frequent-hitters" in drug discovery. The company’s industry-proven molecular design concept is built on groundbreaking algorithms like CATS (Chemically Advanced Template Search) and DOGS (Design Of Genuine Structures) and a unique Collection Of Bioactive Reference Analogs (COBRA) for the discovery of new chemical entities featuring desired properties and tailored polypharmacology. inSili.com's unrivaled target prediction technique enables the "deorphaning" of bioactive agents like natural products and phenotypic screening hits. Own technology development and drug discovery projects continuously strengthen inSili.com's innovation potential.